ArticleBMC bioinformatics2026
SurvMarker: an R package for identifying survival-associated molecular features using PCA-based weighted scores.
Article in BMC bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdentification of prognostic molecular features from high-dimensional molecular data is central to biomarker discovery in cancer and other complex diseases. Principal component analysis (PCA) is widely used for dimensionality reduction in survival studies, yet selecting individual features from principal components (PCs) remains challenging and often relies on arbitrary thresholds. To address this limitation, we developed SurvMarker, an R package that prioritizes survival-associated molecular features using a PCA-based scoring framework.
resultsSurvMarker applies PCA to normalized molecular data, jointly evaluates PCs using multivariable Cox proportional hazards models, and ranks features by aggregating absolute loadings across survival-associated PCs. Feature significance is assessed using an empirical null framework with false discovery rate control. In both synthetic global-null and permutation-based null simulations, SurvMarker showed comparative or better false positive control, particularly in small-n, large-p settings, compared with LASSO Cox, Elastic Net Cox, and Partial Least Squares Cox, while maintaining well-calibrated null p-value distributions. In the TCGA-LAML cohort, SurvMarker achieved the best predictive performance among these methods for gene expression data, with a C-index of 0.78 and an overall time-dependent AUC of 0.882 with similar applicability to miRNA expression data. Compared with sparse PCA-based and fixed per-PC threshold approaches, SurvMarker also achieved better predictive performance and yielded more compact, stable feature sets across different PC settings.
conclusionsSurvMarker provides a robust, interpretable, and reproducible framework for identifying survival-associated molecular features from high-dimensional data. By combining survival-guided PC selection, weighted feature aggregation across PCs, and empirical null-based inference, it improves false discovery control, stability, and biological relevance, and offers a practical tool for biomarker discovery across multiple omics data types.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.